

Product Data Sheet

Product Name: Pramipexole

Cat. No.: GC11960

Chemical Properties

Cas. No. 104632-26-0

Chemical Name (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

SMILES CCCNC1CCC2=C(C1)SC(=N2)N

Formula $C_{10}H_{17}N_3S$ M.Wt 211.33

Solubility $\geq 10.6\text{mg/mL}$ in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Structure



Background

Pramipexole is a dopamine agonist of the non-ergoline class indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS). Target: Dopamine Receptor Pramipexole also possesses low/insignificant affinity (500-10,000 nM) for the 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1D}, and α ₂-adrenergic receptors. It has negligible affinity (>10,000 nM) for the D₁, D₅, 5-HT₂, α ₁-adrenergic, β -adrenergic, H₁, and mACh receptors. All sites assayed were done using human tissues. While pramipexole is used clinically, its D₃-preferring receptor binding profile has made it a popular tool compound for preclinical research. Pramipexole has been used (in combination with D₂- and or D₃-preferring antagonists) to interrogate the role of D₃ receptor function in rodent models and tasks for neuropsychiatric disorders [1-3].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

- [1]. Kvernmo, T., S. Hartter, and E. Burger, A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78.
- [2]. Millan, M.J., et al., Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther, 2002. 303(2): p. 791-804.
- [3]. Weber, M., et al., Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. Behav Pharmacol, 2008. 19(8): p. 786-95.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA